Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
At the 2021 American Society of Hematology (ASH) Annual Meeting, new clinical trial data in nonmalignant hematologic disorders were reported, including novel therapies for acute or chronic graft-vs-host disease (GVHD), hereditary blood disorders (hemophilia and sickle cell disease [SCD]), and acquired blood diseases (paroxysmal nocturnal hemoglobinuria [PNH]).
In this module, David Dingli, MD, PhD; Mark A. Schroeder, MD; and Sujit Sheth, MD, review and discuss the clinical implications of key studies in these hematologic disorders that were presented at the annual ASH meeting.
Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets that can also be found here, each focused on the specific study or topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.
Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: Once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
